Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center and BCAN Scientific Advisor, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.
The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.